Lv1
30 积分 2024-05-21 加入
Progression-Free Survival (PFS) and Toxicity with Nivolumab-AVD Compared to Brentuximab Vedotin-AVD in Pediatric Advanced Stage (AS) Classic Hodgkin Lymphoma (cHL), Results of SWOG S1826
2个月前
已完结
Progression-Free Survival (PFS) and Toxicity with Nivolumab-AVD Compared to Brentuximab Vedotin-AVD in Pediatric Advanced Stage (AS) Classic Hodgkin Lymphoma (cHL), Results of SWOG S1826
2个月前
已关闭
Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report
5个月前
已完结
Correlation Between miR-497-5p Expression With Clinicopathological Characteristics and Prognosis in Patients With Breast Cancer
5个月前
已完结
SWOG S1826, a randomized study of nivolumab(N)-AVD versus brentuximab vedotin(BV)-AVD in advanced stage (AS) classic Hodgkin lymphoma (HL)
6个月前
已完结
PD-1 blockade with pembrolizumab for classical Hodgkin lymphoma after autologous stem cell transplantation
7个月前
已完结
皖公网安备34019202002308
